Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia (Leukemia, (2025), 39, 4, (854-863), 10.1038/s41375-025-02531-8)

Courtney D. DiNardo; Wei Ying Jen; Koichi Takahashi; Tapan M. Kadia; Sanam Loghavi; Naval G. Daver; Lianchun Xiao; Patrick K. Reville; Ghayas C. Issa; Nicholas J. Short; Koji Sasaki; Sa A. Wang; Jillian K. Mullin; Sherry Pierce; Corey Bradley; Gautam Borthakur; Abhishek Maiti; Yesid Alvarado; Naveen Pemmaraju; Alessandra Ferrajoli; Mahesh Swaminathan; Maro Ohanian; Hussein A. Abbas; Danielle Hammond; Jan Burger; Fadi Haddad; Guillermo Montalban-Bravo; Kelly Chien; Lucia Masarova; Musa Yilmaz; Nitin Jain; Michael Andreeff; Guillermo Garcia-Manero; Steven Kornblau; Farhad Ravandi; Elias Jabbour; Marina Y. Konopleva; Hagop M. Kantarjian

doi:10.1038/s41375-025-02827-9

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia (Leukemia, (2025), 39, 4, (854-863), 10.1038/s41375-025-02531-8)

Courtney D. DiNardo
, Wei Ying Jen
, Koichi Takahashi
, Tapan M. Kadia
, Sanam Loghavi
, Naval G. Daver
, Lianchun Xiao
, Patrick K. Reville
, Ghayas C. Issa
, Nicholas J. Short
, Koji Sasaki
, Sa A. Wang
, Jillian K. Mullin
, Sherry Pierce
, Corey Bradley
, Gautam Borthakur
, Abhishek Maiti
, Yesid Alvarado
, Naveen Pemmaraju
, Alessandra Ferrajoli

Mahesh Swaminathan, Maro Ohanian, Hussein A. Abbas, Danielle Hammond, Jan Burger, Fadi Haddad, Guillermo Montalban-Bravo, Kelly Chien, Lucia Masarova, Musa Yilmaz, Nitin Jain, Michael Andreeff, Guillermo Garcia-Manero, Steven Kornblau, Farhad Ravandi, Elias Jabbour, Marina Y. Konopleva, Hagop M. Kantarjian

Oncology

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Abstract

Correction to: Leukemiahttps://doi.org/10.1038/s41375-025-02531-8, published online 25 February 2025 The FLAG-IDA induction comprised fludarabine 30 mg/m² D2–6, cytarabine 1.5 g/m² D2–6, idarubicin 8 mg/m² D4–6, and filgrastim 5 mg/kg D1–7 (Fig. 1). For RR patients, idarubicin was dosed at 6 mg/m² on D4–5. Corrected Fig. 1 (Figure presented.) The original article has been corrected.

Original language	English (US)
Pages (from-to)	262
Number of pages	1
Journal	Leukemia
Volume	40
Issue number	1
DOIs	https://doi.org/10.1038/s41375-025-02827-9
State	Published - Jan 2026

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/s41375-025-02827-9

Fingerprint

Dive into the research topics of 'Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia (Leukemia, (2025), 39, 4, (854-863), 10.1038/s41375-025-02531-8)'. Together they form a unique fingerprint.

Cite this

DiNardo, C. D., Jen, W. Y., Takahashi, K., Kadia, T. M., Loghavi, S., Daver, N. G., Xiao, L., Reville, P. K., Issa, G. C., Short, N. J., Sasaki, K., Wang, S. A., Mullin, J. K., Pierce, S., Bradley, C., Borthakur, G., Maiti, A., Alvarado, Y., Pemmaraju, N., ... Kantarjian, H. M. (2026). Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia (Leukemia, (2025), 39, 4, (854-863), 10.1038/s41375-025-02531-8). Leukemia, 40(1), 262. https://doi.org/10.1038/s41375-025-02827-9

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia (Leukemia, (2025), 39, 4, (854-863), 10.1038/s41375-025-02531-8). / DiNardo, Courtney D.; Jen, Wei Ying; Takahashi, Koichi et al.
In: Leukemia, Vol. 40, No. 1, 01.2026, p. 262.

Research output: Contribution to journal › Comment/debate › peer-review

DiNardo, CD, Jen, WY, Takahashi, K, Kadia, TM, Loghavi, S, Daver, NG, Xiao, L, Reville, PK, Issa, GC, Short, NJ, Sasaki, K, Wang, SA, Mullin, JK, Pierce, S, Bradley, C, Borthakur, G, Maiti, A, Alvarado, Y, Pemmaraju, N, Ferrajoli, A, Swaminathan, M, Ohanian, M, Abbas, HA, Hammond, D, Burger, J, Haddad, F, Montalban-Bravo, G, Chien, K, Masarova, L, Yilmaz, M, Jain, N, Andreeff, M, Garcia-Manero, G, Kornblau, S, Ravandi, F, Jabbour, E, Konopleva, MY & Kantarjian, HM 2026, 'Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia (Leukemia, (2025), 39, 4, (854-863), 10.1038/s41375-025-02531-8)', Leukemia, vol. 40, no. 1, pp. 262. https://doi.org/10.1038/s41375-025-02827-9

@article{b7324b75df994e64a9f9c98478601da6,

title = "Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia (Leukemia, (2025), 39, 4, (854-863), 10.1038/s41375-025-02531-8)",

abstract = "Correction to: Leukemiahttps://doi.org/10.1038/s41375-025-02531-8, published online 25 February 2025 The FLAG-IDA induction comprised fludarabine 30 mg/m2 D2–6, cytarabine 1.5 g/m2 D2–6, idarubicin 8 mg/m2 D4–6, and filgrastim 5 mg/kg D1–7 (Fig. 1). For RR patients, idarubicin was dosed at 6 mg/m2 on D4–5. Corrected Fig. 1 (Figure presented.) The original article has been corrected.",

author = "DiNardo, \{Courtney D.\} and Jen, \{Wei Ying\} and Koichi Takahashi and Kadia, \{Tapan M.\} and Sanam Loghavi and Daver, \{Naval G.\} and Lianchun Xiao and Reville, \{Patrick K.\} and Issa, \{Ghayas C.\} and Short, \{Nicholas J.\} and Koji Sasaki and Wang, \{Sa A.\} and Mullin, \{Jillian K.\} and Sherry Pierce and Corey Bradley and Gautam Borthakur and Abhishek Maiti and Yesid Alvarado and Naveen Pemmaraju and Alessandra Ferrajoli and Mahesh Swaminathan and Maro Ohanian and Abbas, \{Hussein A.\} and Danielle Hammond and Jan Burger and Fadi Haddad and Guillermo Montalban-Bravo and Kelly Chien and Lucia Masarova and Musa Yilmaz and Nitin Jain and Michael Andreeff and Guillermo Garcia-Manero and Steven Kornblau and Farhad Ravandi and Elias Jabbour and Konopleva, \{Marina Y.\} and Kantarjian, \{Hagop M.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2025.",

year = "2026",

month = jan,

doi = "10.1038/s41375-025-02827-9",

language = "English (US)",

volume = "40",

pages = "262",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Correction

T2 - Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia (Leukemia, (2025), 39, 4, (854-863), 10.1038/s41375-025-02531-8)

AU - DiNardo, Courtney D.

AU - Jen, Wei Ying

AU - Takahashi, Koichi

AU - Kadia, Tapan M.

AU - Loghavi, Sanam

AU - Daver, Naval G.

AU - Xiao, Lianchun

AU - Reville, Patrick K.

AU - Issa, Ghayas C.

AU - Short, Nicholas J.

AU - Sasaki, Koji

AU - Wang, Sa A.

AU - Mullin, Jillian K.

AU - Pierce, Sherry

AU - Bradley, Corey

AU - Borthakur, Gautam

AU - Maiti, Abhishek

AU - Alvarado, Yesid

AU - Pemmaraju, Naveen

AU - Ferrajoli, Alessandra

AU - Swaminathan, Mahesh

AU - Ohanian, Maro

AU - Abbas, Hussein A.

AU - Hammond, Danielle

AU - Burger, Jan

AU - Haddad, Fadi

AU - Montalban-Bravo, Guillermo

AU - Chien, Kelly

AU - Masarova, Lucia

AU - Yilmaz, Musa

AU - Jain, Nitin

AU - Andreeff, Michael

AU - Garcia-Manero, Guillermo

AU - Kornblau, Steven

AU - Ravandi, Farhad

AU - Jabbour, Elias

AU - Konopleva, Marina Y.

AU - Kantarjian, Hagop M.

PY - 2026/1

Y1 - 2026/1

N2 - Correction to: Leukemiahttps://doi.org/10.1038/s41375-025-02531-8, published online 25 February 2025 The FLAG-IDA induction comprised fludarabine 30 mg/m2 D2–6, cytarabine 1.5 g/m2 D2–6, idarubicin 8 mg/m2 D4–6, and filgrastim 5 mg/kg D1–7 (Fig. 1). For RR patients, idarubicin was dosed at 6 mg/m2 on D4–5. Corrected Fig. 1 (Figure presented.) The original article has been corrected.

AB - Correction to: Leukemiahttps://doi.org/10.1038/s41375-025-02531-8, published online 25 February 2025 The FLAG-IDA induction comprised fludarabine 30 mg/m2 D2–6, cytarabine 1.5 g/m2 D2–6, idarubicin 8 mg/m2 D4–6, and filgrastim 5 mg/kg D1–7 (Fig. 1). For RR patients, idarubicin was dosed at 6 mg/m2 on D4–5. Corrected Fig. 1 (Figure presented.) The original article has been corrected.

UR - https://www.scopus.com/pages/publications/105027172398

UR - https://www.scopus.com/pages/publications/105027172398#tab=citedBy

U2 - 10.1038/s41375-025-02827-9

DO - 10.1038/s41375-025-02827-9

M3 - Comment/debate

C2 - 41372600

AN - SCOPUS:105027172398

SN - 0887-6924

VL - 40

SP - 262

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia (Leukemia, (2025), 39, 4, (854-863), 10.1038/s41375-025-02531-8)

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this